血浆蛋白制品的病毒相关安全性和合理使用  

The Viral Safety and Rational Use of Plasma Derivative Products

作　　者：高峰[1] 

机构地区：[1]上海市血液中心,上海200051

出　　处：《中国执业药师》2012年第9期37-41,共5页China Licensed Pharmacist

摘　　要：通过一系列努力,我国血浆蛋白制品和病毒相关的安全性得到显著提高,总体上已非常安全。但由于管理和技术等因素的限制,仍然残留一定的通过相关制品经血传播病毒的风险。为此,必须强调血浆蛋白制品的合理使用,严格掌握其适应证,科学确定预期疗效和相应的使用剂量,以保证血浆蛋白制品的疗效并尽可能降低患者可能面对的风险。With systemic efforts the viral safety of human plasma derivative products in China has been significantly improved and the products are safe in general. However, there are still residual risks of transmitting blood-born viruses via the products due to the administrative and technical limitation. It is necessary to emphasize the rational use of the products and be sure that the products are only used for patients with reasonable indications and the target of therapy and dosage of the products are properly determined. Therefore, the effectiveness of the products can be ensured and the risks are avoided as much as possible.

关 键 词：血浆蛋白制品 经血传播病毒 适应证 

分 类 号：R392-33[医药卫生—免疫学]